Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine

Max Gelman

Senior Editor

Vaxcyte shares $PCVX jumped more than 40% Tuesday morning on the heels of Phase 1/2 data for its 31-valent pneumococcal conjugate vaccine, VAX-31, being tested …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

Up­dat­ed: Vax­cyte surges on Phase 1/2 da­ta for 31-va­lent pneu­mo­coc­cal vac­cine

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine